Research programme: helminth-derived peptide therapeutics - Helmedix
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator Helmedix; University of Technology Sydney
- Developer Helmedix
- Class Peptides
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Australia
- 19 Feb 2013 Research programme: immunomodulating peptide therapeutics - Helmedix is available for licensing as of 14 Feb 2013.
- 14 Feb 2013 Early research in Autoimmune disorders in Australia (unspecified route)